Loading…
Annovis Bio, Inc. is projected to rise to $2.29 by 2027, a +23% move from its current price of $1.86. ANVS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $1.80 | $1.86 | $1.92 | -0.03% |
| Jul 13 | $1.78 | $1.86 | $1.94 | -0.06% |
| Jul 14 | $1.76 | $1.86 | $1.96 | -0.09% |
| Jul 15 | $1.74 | $1.86 | $1.98 | -0.13% |
| Jul 16 | $1.73 | $1.86 | $1.99 | -0.16% |
| Jul 17 | $1.72 | $1.86 | $2.01 | -0.19% |
| Jul 18 | $1.71 | $1.86 | $2.02 | -0.22% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.71 | $1.86 | $2.02 | -0.22% |
| Week 2 | $1.65 | $1.85 | $2.08 | -0.44% |
| Week 3 | $1.60 | $1.85 | $2.13 | -0.66% |
| Week 4 | $1.56 | $1.84 | $2.18 | -0.87% |
| Week 5 | $1.53 | $1.84 | $2.22 | -1.09% |
| Week 6 | $1.50 | $1.84 | $2.25 | -1.31% |
| Week 7 | $1.47 | $1.83 | $2.28 | -1.52% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Annovis Bio, Inc. is a healthcare company described as a clinical stage drug platform focused on neurodegeneration in the United States.
Its lead product candidate is Buntanetap, which is in phase 3 to treat Alzheimer's disease, as well as in open-label phase 3 to treat Parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of Alzheimer's disease and dementia.
Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Annovis Bio, Inc. (ANVS) is a healthcare company with a clinical stage drug platform focused on neurodegeneration in the United States. The stock currently trades at $1.86 per share and has a market cap of $79.13M, placing it in a mid-cap range by market standards and ranked 4115.
The near-term price outlook is guided by year-by-year forecasts that show a gradual upward trajectory beginning in 2027, with stronger upside projected into the 2030s and beyond. The forecast for 2026 lists an average price of $1.86, and the long-range view sees the average price rising substantially toward $8.62 by 2050, with max projections climbing as high as $17.75.
These estimates imply meaningful upside potential over the multi-year horizon, with varying upside by year (e.g., 2027 avg $2.44, 2028 $2.62, 2030 $2.69, 2040 $4.98, 2050 $8.62) and corresponding ROI figures up to 363.6% by 2050. Such forecasts are not guarantees and should be weighed against inherent investment risk.
A major floor 19.7% below — a decisive break under it would weaken the trend.
The nearest floor, 11.3% below — buyers have tended to step in here.
The nearest ceiling, 7.0% above — a clean break opens room to run.
A major ceiling 52.2% above — clearing it would confirm fresh momentum.
Key ANVS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ANVS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.94 | Sell | $1.91 | Sell |
| MA 10 | $1.90 | Sell | $1.89 | Sell |
| MA 20 | $1.83 | Buy | $1.87 | Sell |
| MA 50 | $1.96 | Sell | $1.94 | Sell |
| MA 100 | $2.12 | Sell | $2.13 | Sell |
| MA 200 | $2.53 | Sell | $2.46 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.68 | Neutral |
| Stoch RSI (14) | 56.93 | Neutral |
| CCI (20) | 27.54 | Neutral |
| Williams %R (14) | -38.24 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | 6.90 | Buy |
| Bollinger %B (20,2) | 0.59 | Neutral |
| Stochastic %K (14) | 61.76 | Neutral |
| TRIX (15) | -0.17 | Sell |
| Awesome (5,34) | 0.07 | Buy |
| Ultimate (7,14,28) | 51.93 | Neutral |
| Momentum (10) | 0.21 | Buy |
| Aroon Osc (25) | 32.00 | Buy |
| Hull MA (9) | 1.95 | Sell |
| ADX (14) | 12.64 | Neutral |
| ATR (14) | 0.06 | Info |
The 30-day technical picture is neutral, with RSI(14) at 50 and moving averages around the current level. The SMA50 stands at $1.95 and the SMA200 at $2.55, framing price action near key moving averages.
Support is identified at $1.65 and resistance at $2.23, with the 30-day price range between $1.47 and $2.35. The stock exhibits elevated volatility, with annualized volatility listed at 70%, underscoring a potentially higher risk-return profile in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.59 | $1.86 | $2.24 | 0% | Neutral | |
| $1.80 | $2.29 | $3.11 | +23% | Bullish | |
| $1.91 | $2.51 | $3.54 | +35% | Bullish | |
| $1.79 | $2.43 | $3.54 | +31% | Bullish | |
| $1.83 | $2.53 | $3.79 | +36% | Bullish | |
| $1.71 | $2.42 | $3.71 | +30% | Bullish | |
| $1.74 | $2.52 | $3.95 | +36% | Bullish | |
| $1.97 | $2.91 | $4.64 | +56% | Bullish | |
| $2.15 | $3.23 | $5.25 | +74% | Bullish | |
| $2.35 | $3.59 | $5.93 | +93% | Bullish | |
| $2.64 | $4.38 | $7.75 | +135% | Bullish | |
| $3.95 | $7.55 | $14.74 | +306% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.59 | $1.86 | $2.25 | +0.00% |
| August 2026 | $1.54 | $1.82 | $2.22 | -2.00% |
| September 2026 | $1.51 | $1.81 | $2.23 | -0.84% |
| October 2026 | $1.54 | $1.86 | $2.32 | +2.68% |
| November 2026 | $1.51 | $1.82 | $2.30 | -1.72% |
| December 2026 | $1.45 | $1.76 | $2.24 | -3.44% |
Click any year to see its month-by-month ANVS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ANVS price prediction for 2026 points to an average of $1.86 (low $1.59, high $2.24) — a potential gain of 0% on today's $1.86. A consolidation phase looks the most probable path here.
In 2027, ANVS is projected to trade between $1.80 and $3.11, averaging $2.29 — a potential gain of +23% from today's $1.86. That is up +23% on the projected 2026 average. Momentum favours further upside here.
Annovis Bio, Inc.'s 2028 outlook centres on $2.51, within a $1.91 to $3.54 range. That is up +9% on the projected 2027 average. That marks a +35% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, ANVS could reach as high as $3.54, with a base case around $2.43 and support toward $1.79 — roughly +31% from $1.86. Momentum favours further upside here.
Expect ANVS to range from $1.83 to $3.79 through 2030. The $2.53 average target implies a +36% move from current prices. That is up +4% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The ANVS price prediction for 2031 points to an average of $2.42 (low $1.71, high $3.71) — a potential gain of +30% on today's $1.86. Momentum favours further upside here.
In 2032, ANVS is projected to trade between $1.74 and $3.95, averaging $2.52 — a potential gain of +36% from today's $1.86. That is up +4% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Annovis Bio, Inc.'s 2033 outlook centres on $2.91, within a $1.97 to $4.64 range. That is up +15% on the projected 2032 average. That marks a +56% change versus current levels. Momentum favours further upside here.
By 2034, ANVS could reach as high as $5.25, with a base case around $3.23 and support toward $2.15 — roughly +74% from $1.86. Buyers look set to stay in control over this stretch.
Expect ANVS to range from $2.35 to $5.93 through 2035. The $3.59 average target implies a +93% move from current prices. That is up +11% on the projected 2034 average. Momentum favours further upside here.
The ANVS price prediction for 2040 points to an average of $4.38 (low $2.64, high $7.75) — a potential gain of +135% on today's $1.86. Buyers look set to stay in control over this stretch.
In 2050, ANVS is projected to trade between $3.95 and $14.74, averaging $7.55 — a potential gain of +306% from today's $1.86. That is up +72% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in ANVS today (≈ 537.634409 ANVS) could be worth
$4,058.39
+$3,058.39 (+306%) by 2050 · US Dollar
Based on the average projected ANVS price of $7.55 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ANVSwould be worth at today's price.
$1,000 invested in ANVS on Jul 10, 2025 (≈ 350.877205 ANVS) would be worth
$652.63
-$347.37 (-34.7%) today · 0.65× · US Dollar
Based on a ANVS entry price of $2.85 vs. today's $1.86.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.93 | $963.73 | -3.6% |
| 1 month ago | $1.72 | $1,081.4 | +8.1% |
| 3 months ago | $1.59 | $1,169.81 | +17.0% |
| 6 months ago | $3.45 | $539.13 | -46.1% |
| 1 year ago | $2.85 | $652.63 | -34.7% |
| All time (5.0y) ago | $117.26 | $15.86 | -98.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ANVS forecast.
Our base-case forecast reaches $3.70 around 2040.
Implied market cap at $3.70: $157.4M
The multi-year forecast points to a bullish trajectory, with the average price rising from $1.86 in 2026 to $8.62 by 2050. Notable intermediate milestones include a 2027 average of $2.44 (ROI 31.3%) and a 2030 average of $2.69 (ROI 44.8%), followed by a 2040 average of $4.98 (ROI 167.5%) and a 2050 average of $8.62 (ROI 363.6%). The forecast also shows substantial upside in later years, with a 2033 average of $3.26 (ROI 75.4%) and a 2034 average of $3.55 (ROI 91%).
Sentiment shifts from NEUTRAL in 2026 to BULLISH from 2027 onward, reflecting a constructive longer-term outlook despite near-term uncertainty. Key risks include the usual caveats of equity forecasting and clinical-stage drug development outcomes, which can impact realized returns and timing.
Tap a question to reveal the answer.
The forecasted average price in 2030 is $2.69, with a min of $1.89 and a max of $4.16, and an expected ROI of 44.8%, with bullish sentiment noted for that period.
Forecasts project bullish sentiment from 2027 onward, with the average price rising to $8.62 by 2050 and a maximum implied ROI of up to 363.6%, though these are estimates and not guarantees.
Yes. The yearly forecast shows a max of $5.41 in 2033, with higher maxima in later years (2034 max $6.00; 2035 max $6.90; 2040 max $9.21; 2050 max $17.75).
Current price is $1.86 and market cap is $79.13M, with a rank of 4115.
The 30-day range is between $1.47 and $2.35.
Annovis Bio, Inc. Community Discussion
0Share your Annovis Bio, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.